- University / research
- Country: United States
Targeting the YAP1/TAZ-TEAD Transcriptional Axis Reveals a Therapeutic Vulnerability in Androgen Receptor Signaling Inhibitor (ARSI)-Resistant Prostate Cancer
Therapeutic resistance remains a major barrier in advanced prostate cancer (PCa), particularly after prolonged treatment with second-generation androgen receptor signaling inhibitors (ARSIs) such as enzalutamide. Tumors can evade these drugs by escaping androgen receptor (AR) dependence through…